Many times investors make their stock choices based on how they climb in value on the market. However, savvy investors should also consider the companies that are setting the stage for a series of future significant milestones. Their cutting-edge products will be tapped by thousands of people, and the companies may make for future solid investment.
Let’s look at a company that must be given credit for its contributions to the pharmaceutical industry. Its emerging products will benefit many people affected by breast cancer. One of its treatment studies include CDX-011. The treatment is a conjugate that binds to a specific protein that promotes the migration, invasion, and metastasis of the disease. The company’s results demonstrate overall survival benefits.
CD-011 is the brainchild of Celldex Therapeutics (NASDAQ: CLDX). Since it announced the final results from its study, its stock has risen to $5 a share. While I think its great that Celldex is making progress with CD-011, that’s not the only thing that gets me excited by the stock. The breast cancer treatment is one in a line of studies carried out by the company. What piques my interest are the areas – outside breast cancer – that the company is studying. Another of its ongoing studies is on a vaccine that may act to promote anti-cancer effects in patients who have glioblastoma, a type of brain cancer.
“These events, coupled with ongoing activity in a number of other projects, will set the stage for a series of future milestones,” said Anthony Markucci, the CEO of Celldex while delivering the company’s third quarter report for the nine months ended September 30, 2012.
Celldex reported cash, cash equivalents, and marketing securities of $77.6 million, which the company believes will be sufficient to meet estimated working capital requirements and fund planned for program development into 2014. The decrease of $1.1 million from June 30, 2013 is due primarily to increased operational expenses during the quarter related to the vaccine on brain tumor. However, the cash outflows for these expenses were offset by the issuance of $2.0 million shares that raised net proceeds to Celldex of $10.9 million.
Sure, Celldex reported a net loss of $15 million for the third quarter of 2012 compared with a net loss of $11.8 million for the third quarter of 2011. It reported a net loss of $47.3 million for the nine months ended September 30, 2012, compared to a net loss of $32.1 million for the nine months ended September 30, 2011. But that is primarily due to increased operational expenses related to its studies.
Its competitors in the diagnostic substances industry are Dendreon Corp (NASDAQ: DNDN), Eli Lilly and Company (NYSE: LLY), and Roche Holding AG (NASDAQ: RHHBY). Trading at about $7.30 per share, its market cap is about $470 million. The decision as to whether to trade in Celldex in the first place rests with the individual trader. But if you want to place a pharmaceutical company on your watch list for 2013 and beyond, consider Celldex. Its emerging products may prove to be as strong as those produced by the world’s most valuable pharmaceutical companies.